Table of Contents

• Overview of BP1.4979
• Understanding Binge Eating Disorder (BED)
• The Clinical Study on BP1.4979
• Eligibility Criteria for the Study
• Study Endpoints: Measuring Effectiveness
• Potential Implications for Patients

Overview of BP1.4979

BP1.4979 is an investigational drug being studied for the treatment of binge eating disorder (BED) in women. Its scientific name is N-[4-[2-[4-(3-CYANOPHENYL)PIPERAZIN-1-YL]ETHYL]CYCLOHEXYL]-3-METHOXYPROPANAMIDE^[1]. This medication is being developed as a potential new option for patients struggling with moderate to severe BED symptoms.

Understanding Binge Eating Disorder (BED)

Binge eating disorder is a serious mental health condition characterized by recurring episodes of eating large quantities of food in a short period, often to the point of discomfort. People with BED typically feel a loss of control during these episodes and may experience feelings of shame, distress, or guilt afterward^[1]. It’s important to note that BED is different from other eating disorders like bulimia nervosa or anorexia nervosa.

The Clinical Study on BP1.4979

A clinical trial is being conducted to assess the effectiveness and safety of BP1.4979 for treating BED. Here are some key points about the study:

• It’s a Phase II study, which means it’s testing the drug’s effectiveness and looking for side effects in a larger group of people^[1].
• The study is double-blind and placebo-controlled. This means that neither the participants nor the researchers know who is receiving the actual drug and who is receiving a placebo (a substance with no active ingredients). This helps ensure unbiased results^[1].
• The dosage being tested is 15 mg, taken twice daily (abbreviated as BID, which stands for “bis in die” in Latin, meaning twice a day)^[1].
• The study focuses on female patients aged 18 to 65 with moderate to severe BED symptoms^[1].

Eligibility Criteria for the Study

To participate in the study, patients must meet certain criteria. Some key inclusion criteria are:

• Female, aged 18-65 years^[1].
• Diagnosed with BED according to DSM-5 criteria (DSM-5 is the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, used by mental health professionals to diagnose conditions)^[1].
• At least two binge-eating days per week and at least 8 episodes during the 2 weeks prior to starting the study medication^[1].

Some exclusion criteria (reasons why someone cannot participate) include:

• Current diagnosis of bulimia nervosa or anorexia nervosa^[1].
• Recent use of psychostimulants for weight loss or dieting^[1].
• History of certain psychiatric disorders or ongoing alcohol addiction treatment^[1].
• Pregnancy or inadequate contraception use^[1].

Study Endpoints: Measuring Effectiveness

The study will measure several outcomes to determine if BP1.4979 is effective. The main (primary) endpoint is:

• The change in the total number of binge-eating episodes per week, comparing the 2 weeks before starting treatment to the last 2 weeks of the 8-week treatment period^[1].

Secondary endpoints (additional measures of effectiveness) include:

• Changes in food addiction symptoms, measured by the Yale Food Addiction Scale^[1].
• Overall improvement in BED symptoms, assessed by the Clinical Global Impression scale^[1].
• Changes in the number of binge-eating days per week^[1].

Potential Implications for Patients

If BP1.4979 proves to be safe and effective in this study, it could potentially offer a new treatment option for women struggling with binge eating disorder. However, it’s important to remember that this is still an investigational drug, and more research will be needed before it can be approved for general use.

Patients with BED should continue to work with their healthcare providers to manage their condition using currently approved treatments and therapies. If you’re interested in participating in clinical trials for BED, you can discuss this with your doctor or search for trials in your area on reputable clinical trial registry websites.